Skip to content Skip to sidebar Skip to footer
Subscribe Now
Thoughtspot_Saurabh Chaubey
THOUGHTSPOT

Reinventing Marketing Strategies for Biopharma Companies

Shots: Conventional marketing strategies face challenges due to a lack of next-generation tools integrated into existing models. Explore the nuances of biopharma marketing, highlighting its key elements and the advantages it offers. Discover PharmaShots’ 4D model, which has been instrumental in shaping the biopharma marketing landscape. Strategically crafted marketing plans are essential for long-term sustainability,…
January 22, 20250Comments

Read more

ThoughtSpot_Evans James
THOUGHTSPOT

How ABA Software Can Save Time and Reduce Errors in Therapy Billing

Therapy billing is a critical yet often complicated part of running an Applied Behavior Analysis (ABA) practice. The process of managing invoices, insurance claims, and financial records requires precision and significant administrative effort. For small practices, the burden of manual billing can lead to inefficiencies, errors, and delayed payments. ABA software offers a streamlined solution,…
January 22, 20250Comments

Read more

News

Antennova to Highlight P-I/II (CLINCH) Trial Data of ATN-022 to Treat Advanced/Metastatic Gastric Cancer at ASCO GI 2025

Shots:The company will highlight data from P-I/II (CLINCH) trial of ATN-022 to treat advanced/metastatic gastric cancer in Australia & China at ASCO GI 2025 under the title, ‘Safety and Preliminary Efficacy of ATG-022 in Patients with Advanced/Metastatic Gastric Cancer (CLINCH)’ In the dose expansion phase (as of Nov 2024), 21 patients with CLDN18.2…
January 22, 20250Comments

Read more

News

Solid Biosciences’ SGT-212 Secures the US FDA’s Fast Track Designation for Treating Friedreich’s Ataxia

Shots:The US FDA has granted FTD to SGT-212 for treating Friedreich’s ataxia (FA) and previously approved its IND on Jan 07, 2025 The P-Ib study will assess safety & tolerability of contemporaneous systemic IV and bilateral IDN administration of SGT-212 in non-ambulatory and ambulatory FA patients for 5yrs., with dosing anticipated during H2’25…
January 22, 20250Comments

Read more

Sanofi
News

The EC Approves Sanofi’s Sarclisa + standard-of-care VRd to Treat Newly Diagnosed Multiple Myeloma (NDMM)

Shots:The EC has approved Sarclisa with SoC VRd (bortezomib, lenalidomide, & dexamethasone) to treat ASCT-ineligible NDMM patients, following the CHMP’s positive opinion. Regulatory findings are under review in Japan & China Approval was based on a P-III (IMROZ) study assessing Sarclisa + VRd vs VRd, which showed improved PFS of 40% (1EP) with findings reported…
January 22, 20250Comments

Read more

Roche
News

Roche Receives 510(k) Clearance & CLIA Waiver for Cobas Liat Multiplex Assay Panels to Diagnose Sexually Transmitted Infections

Shots:The US FDA has granted 510(k) clearance & CLIA waiver for Cobas liat STI multiplex assay panels (CT/NG & CT/NG/MG), commercially available under the CE mark in upcoming months The CT/NG (chlamydia & gonorrhea) & CT/NG/MG (chlamydia, gonorrhea & Mycoplasma genitalium) assays compliment the existing portfolio of singleplex & multiplex tests of Cobas liat…
January 22, 20250Comments

Read more

News

ArriVent Biopharma Collaborates with Lepu BioPharma to Develop and Commercialize MRG007 for the Treatment of Gastrointestinal Cancers

Shots:ArriVent & Lepu Biopharma entered into an exclusive license agreement for MRG007, where ArriVent will get rights to develop & market MRG007 (ADC) globally excl. Greater China (mainland China, Hong Kong, Macau & Taiwan) As per the terms, Lepu Biopharma will receive upfront, near-term milestones ($47M cash) & development, regulatory & sales milestones…
January 22, 20250Comments

Read more